Regenxbio receives FDA fast track designation for RGX-121 gene therapy for the treatment of MPS II

May 2, 2018 at 7:00 AM EDT -- Novel, one-time, direct-to-CNS investigational treatment for MPS II designed to prevent the progression of cognitive deficits-- Phase I/II clinical trial expected to enroll children with MPS II-- Expect to initiate patient recruitment and dosing in mid-2018 ROCKVILLE, Md., May 2, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a [...]